8-K current report · filed Oct 22, 2026

SUPERNUS PHARMACEUTICALS, INC. (SUPN) 8-K Current Report: October 22, 2026

Item 8.01Item EX-99.1SUPN overview

Short answer

SUPERNUS PHARMACEUTICALS, INC. (SUPN) filed an 8-K current report with the SEC on October 22, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). FDA-recognized seven-year orphan-drug exclusivity for ONAPGO, protecting market position through February 3, 2032.

SUPERNUS PHARMACEUTICALS, INC. 8-K event analysis

AI summary of each reported item and its exhibits

Item 8.01 · Other Events

  • FDA-recognized seven-year orphan-drug exclusivity for ONAPGO, protecting market position through February 3, 2032
  • ONAPGO approved for motor fluctuations in adults with advanced Parkinson’s disease
  • Supplemental application submitted for a second ONAPGO supplier, targeting potential FDA approval by mid-2027
  • Additional supplier could reduce manufacturing concentration and support commercial supply resilience

Item EX-99.1 · Exhibit EX-99.1

  • ONAPGO receives seven years of U.S. orphan-drug exclusivity, supporting pricing protection through February 3, 2032
  • Exclusivity strengthens Supernus’s commercial position for Parkinson’s motor-fluctuation treatment
  • sNDA submitted for a second ONAPGO supplier, targeting potential FDA approval by mid-year 2027
  • Additional supplier could reduce manufacturing concentration and improve supply reliability after earlier supply issues

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other SUPERNUS PHARMACEUTICALS, INC. 8-K filings

Get the next SUPN 8-K as it lands

Follow SUPN for push alerts, or ask the research agent what this filing means.